FG-3246 and Enzalutamide Combination Therapy Shows Promising Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Source: Globenewswire
- Significant Efficacy: The combination of FG-3246 and enzalutamide demonstrated a median radiographic progression-free survival (rPFS) of 7.0 months in biomarker-unselected metastatic castration-resistant prostate cancer (mCRPC) patients, with a notable 10.1 months in those who had only one prior ARPI, highlighting FG-3246's potential in earlier treatment lines.
- Biomarker Potential: Higher tumor uptake of FG-3180 showed a trend towards a higher probability of PSA50 response (p=0.053), indicating FG-3180's potential as a significant biomarker for patient selection, thereby enhancing the clinical applicability of FG-3246.
- Safety Validation: The safety profile of the combination therapy was similar to that observed in the previous Phase 1 trial of FG-3246, with the risk of neutropenia effectively mitigated through G-CSF prophylaxis, suggesting the clinical feasibility of this combination treatment.
- Trial Progress: The Phase 2 monotherapy trial of FG-3246 is on track for interim analysis in the second half of 2026, which will further validate its efficacy and safety in treating metastatic castration-resistant prostate cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
